Atacicept in Multiple Sclerosis, Phase II

This study has been terminated.
(EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in the atacicept treatment groups compared to placebo)
Sponsor:
Information provided by:
EMD Serono
ClinicalTrials.gov Identifier:
NCT00642902
First received: March 21, 2008
Last updated: April 22, 2011
Last verified: April 2011
  Purpose

To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces Central Nervous System inflammation in subjects with RMS as assessed by frequent MRI. This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.


Condition Intervention Phase
Relapsing Multiple Sclerosis
Drug: atacicept
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, Multicentre Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of Three Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS)

Resource links provided by NLM:


Further study details as provided by EMD Serono:

Primary Outcome Measures:
  • Mean number of T1 gadolinium (Gd)-enhancing lesions per subject per scan. [ Time Frame: up to 48 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of new T1 hypointense lesions, Proportion of subjects free from relapses during the 36-week treatment period, Nature, severity, and incidence of adverse events and infections [ Time Frame: weeks 12, 24, 36 ] [ Designated as safety issue: No ]

Estimated Enrollment: 292
Study Start Date: March 2008
Study Completion Date: February 2011
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
High-dose treatment with Atacicept
Drug: atacicept
Atacicept high, mid and low-dose, respectively
Experimental: 2
Mid-dose treatment with Atacicept
Drug: atacicept
Atacicept high, mid and low-dose, respectively
Experimental: 3
Low dose treatment with Atacicept
Drug: atacicept
Atacicept high, mid and low-dose, respectively
Placebo Comparator: 4
Placebo
Drug: Placebo
Placebo will be supplied in a transparent, sterile solution for injection in pre-filled syringes matching the Atacicept pre-filled syringes, each containing 1mL. The placebo formulation to be used in this study contains trehalose and 10 mmol sodium acetate buffer (pH 5)."

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Relapsing Multiple Sclerosis (per McDonald criteria, 2005);

Exclusion Criteria:

  • Have primary progressive MS.
  • Have secondary progressive MS without superimposed relapses.
  • Relevant cardiac, hepatic and renal diseases
  • Pre treatment with immunosuppressants and immunomodulating drugs
  • Clinical significant abnormalities in blood cell counts and Ig levels
  • Clinical significant acute or chronic infections.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00642902

  Show 51 Study Locations
Sponsors and Collaborators
EMD Serono
Investigators
Study Director: Dan Mikol, MD, PhD EMD Serono
  More Information

Additional Information:
No publications provided

Responsible Party: Lynne Macgregor, Merck Serono S.A. - Geneva an Affiliate of Merck KGaA Darmstadt, Germany
ClinicalTrials.gov Identifier: NCT00642902     History of Changes
Other Study ID Numbers: 28063
Study First Received: March 21, 2008
Last Updated: April 22, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on August 18, 2014